Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New
Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer
Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in
patients with triple class refractory multiple myeloma.